Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2009

View Archived Issues

Oxcarbazepine reduces pain in Parkinson's disease patients

CD40L gene therapy shows promise in urothelial bladder cancer trial

Calixa Therapeutics announces successful completion of phase I study of CXA-101

Endo completes acquisition of Indevus

Toyama and Eisai to conduct additional study for T-614 and resubmit NDA

Shire reviews Q4 activities and looks ahead to upcoming milestones

Novel histamine H3 receptor antagonists claimed in AstraZeneca patent

Ono Pharmaceutical prepares and tests novel prostanoid DP receptor antagonists

Advaxis updates phase I trial survival data for ADXS-11-001

Orexo announces phase IIa data on OX-914 in allergic rhinitis

Celsion receives orphan drug designation for ThermoDox in liver cancer

Epiphany Biosciences to file IND to study valomaciclovir adjunctive therapy in MS

Morphotek and Eisai commence FDA SPA phase III farletuzumab trial

Genfit acquires type 2 diabetes and obesity program from Merck Sante

Novel antiviral candidate for the treatment of chronic hepatitis C is discovered

Radius initiates phase IIa RAD-1901 trial in menopausal hot flashes

Rexahn receives FDA approval to begin phase II trials for Archexin in pancreatic cancer

Dual inhibitor of Fms/Kit described by Plexxikon for the treatment of autoimmune conditions

Avexa reaches 16-week evaluation point in phase III trial of apricitabine in HIV

WAY-262611 acts as a Wnt beta-catenin agonist, increases bone formation in osteoporosis model

PF-0419789, mutant B-Raf inhibitor, synthesized at Pfizer

ACT-077825 generally well tolerated, decreases blood pressure in first-in-human study

DSMB recommends continuation of phase III trial of Vical's Allovectin-7

Vantia presents update on preclinical and clinical development portfolios

Syndax Pharmaceuticals describes sirtuin modulators for cancer treatment

Lilly presents novel gamma-secretase inhibitors

Novel histamine H1 receptor antagonists described by GlaxoSmithKline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...